New pandemics are a serious threat to the health of the entire …

• Abstract
• Background
• References

Biology Articles » Virology » New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu » References

References

- New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

   Lancet 2006, 367:817-824.

2. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholie S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.

   Lancet 2006, 367:1981-1989.

3. Elenga N, Kouakoussui KA, Bonard D, Fassinou P, Anaky MF, Wemin ML, Dick-Amon-Tanoh F, Rouet F, Vincent V, Msellati P: Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study.

   Pediatr Infect Dis J 2005, 24:1077-1082.

4. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

   PLoS Med 2005, 2:e298.

5. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, Rouzioux C, Resch M, Guillet JG, Kazatchkine M, Delfraissy JF, Aboulker JP: Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.

   AIDS 2006, 20:405-413.

6. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH: Distribution and three-dimensional structure of AIDS virus envelope spikes.

   Nature 2006, 441:847-852.

7. Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH: Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

   Proc Natl Acad Sci USA 2003, 100:15812-15817.

8. Chertova E, Bess JW Jr, Crise BJ, Sowder IR, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO: Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

   J Virol 2002, 76:5315-5325.

9. Rajkowitsch L, Semrad K, Mayer O, Schroeder R: Assays for the RNA chaperone activity of proteins.

   Biochem Soc Trans 2005, 33:450-456.

10. Schroeder R, Barta A, Semrad K: Strategies for RNA folding and assembly.

    Nat Rev Mol Cell Biol 2004, 5:908-919.

11. Waldsich C, Grossberger R, Schroeder R: RNA chaperone StpA loosens interactions of the tertiary structure in the td group I intron in vivo.

    Genes Dev 2002, 16:2300-2312.

12. Ivanyi-Nagy R, Kanevsky I, Gabus C, Lavergne JP, Ficheux D, Penin F, Fosse P, Darlix JL: Analysis of hepatitis C virus RNA dimerization and core-RNA interactions.

    Nucleic Acids Res 2006, 34:2618-2633.

13. Darlix JL, Lapadat-Tapolsky M, de Rocquigny H, Roques BP: First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses.

    J Mol Biol 1995, 254:523-537.

14. Bampi C, Bibillo A, Wendeler M, Divita G, Gorelick RJ, Le Grice SF, Darlix JL: Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein.

    J Biol Chem 2006, 281:11736-11743.

15. Druillennec S, Dong CZ, Escaich S, Gresh N, Bousseau A, Roques BP, Fournie-Zaluski MC: A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

    Proc Natl Acad Sci USA 1999, 96:4886-4891.

16. Raja C, Ferner J, Dietrich U, Avilov S, Ficheux D, Darlix JL, de Rocquigny H, Schwalbe H, Mely Y: A tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein.

    Biochemistry 2006, 45:9254-9265.

17. Scozzafava A, Casini A, Supuran CT: Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs.

    Curr Med Chem 2002, 9:1167-1185.

18. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

    Nat Med 2005, 11:791-796.

19. Hourioux C, Ait-Goughoulte M, Patient R, Fouquenet D, Arcanger F, Brand D, Martin A, Roingeard P: Core protein domains involved in hepatitis C virus-like particle assembly and morphogenesis at the endoplasmic reticulum membrane.

    Cell Microbiol, in press.

20. Ait-Goughoulte M, Hourioux C, Patient R, Trassard S, Brand D, Roingeard P: Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly.

    J Gen Virol 2006, 87:855-860.

21. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G: euHCVdb: the European hepatitis C virus database.

    Nucleic Acids Res 2007, 35:D363-D366.

22. [http://euhcvdb.ibcp.fr]

23. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus.

    Hepatology 2004, 39:5-19.

24. Mouland AJ, Heveker N, Gatignol A: Virus-Cell Interactions.In Encyclopedia of Molecular Cell Biology and Molecular Medicine. Volume 15. 2nd edition. Edited by: Meyers RA. Wiley-VCH Verlag Weinheim, Germany; 2005:423-484.

25. Tardif MR, Tremblay MJ: Regulation of LFA-1 activity through cytoskeleton remodeling and signaling components modulates the efficiency of HIV type-1 entry in activated CD4+ T lymphocytes.

    J Immunol 2005, 175:926-935.

26. Tardif MR, Tremblay MJ: LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1.

    J Virol 2005, 79:13714-13724.

27. Huang LM, Joshi A, Willey R, Orenstein J, Jeang K-T: Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

    EMBO J 1994, 13:2886-2896.

28. Bennasser Y, Jeang KT: HIV-1 Tat interaction with Dicer: requirement for RNA.

    Retrovirology 2006, 3:95.

29. Bennasser Y, Le SY, Benkirane M, Jeang KT: Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing.

    Immunity 2005, 22:607-619.

30. Yeung ML, Bennasser Y, Myers TG, Jiang G, Benkirane M, Jeang KT: Changes in microRNA expression profiles in HIV-1-transfected human cells.

    Retrovirology 2005, 2:81.

31. Herbreteau CH, Weill L, Decimo D, Prevot D, Darlix JL, Sargueil B, Ohlmann T: HIV-2 genomic RNA contains a novel type of IRES located downstream of its initiation codon.

    Nat Struct Mol Biol 2005, 12:1001-1007.

32. Bannwarth S, Lainé S, Daher A, Grandvaux N, Clerzius G, Leblanc AC, Hiscott J, Gatignol A: Cell-specific regulation of TRBP1 promoter by NF-Y transcription factor in lymphocytes and astrocytes.

    J Mol Biol 2006, 355:898-910.

33. Ong CL, Thorpe JC, Gorry PR, Bannwarth S, Jaworowski A, Howard JL, Chung S, Campbell S, Christensen HS, Clerzius G, Mouland AJ, Gatignol A, Purcell DF: Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response.

    J Virol 2005, 79:12763-12772.

34. Haase AD, Jaskiewicz L, Zhang H, Lainé S, Sack R, Gatignol A, Filipowicz W: TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing.

    EMBO Rep 2005, 6:961-967.

35. Gatignol A, Lainé S, Clerzius G: Dual role of TRBP in HIV replication and RNA interference: viral diversion of a cellular pathway or evasion from antiviral immunity?

    Retrovirology 2005, 2:65.

36. Freed EO, Mouland AJ: The cell biology of HIV-1 and other retroviruses.

    Retrovirology 2006, 3:77.

37. Morita E, Sundquist WI: Retrovirus budding.

    Annu Rev Cell Dev Biol 2004, 20:395-425.

38. Grigorov B, Arcanger F, Roingeard P, Darlix JL, Muriaux D: Assembly of infectious HIV-1 in human epithelial and T-lymphoblastic cell lines.

    J Mol Biol 2006, 359:848-862.

39. Tanchou V, Decimo D, Pechoux C, Lener D, Rogemond V, Berthoux L, Ottmann M, Darlix JL: Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication.

    J Virol 1998, 72:4442-4447.

40. Cimarelli A, Sandin S, Hoglund S, Luban J: Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.

    J Virol 2000, 74:3046-3057.

41. Finzi A, Brunet A, Xiao Y, Thibodeau J, Cohen EA: Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments.

    J Virol 2006, 80:9789-9797.

42. Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J: Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.

    J Virol 2006, 80:2832-2841.

43. Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.

    J Exp Med 2003, 197:633-642.

44. Hiscott J, Lin R, Nakhaei P, Paz S: MasterCARD: a priceless link to innate immunity.

    Trends Mol Med 2006, 12:53-56.

45. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S: Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses.

    Oncogene 2006, 25:6844-6867.

46. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J: Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

    Nature 2005, 437:1167-1172.

47. Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E, Hiscott J: Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage.

    J Virol 2006, 80:6072-6083.

48. Sayah DM, Sokolskaja E, Berthoux L, Luban J: Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.

    Nature 2004, 430:569-573.

49. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

    Nature 2004, 427:848-853.

50. Luban J: Cyclophilin A, TRIM5, and Resistance to HIV-1 Infection.

    J Virol 2007, 81:1054-1061.

51. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O: Inefficient HIV replication in mobile lymphocytes.

    J Virol 2007, 81:1000-1012.

52. Thoulouze MI, Sol-Foulon N, Blanchet F, Dautry-Varsat A, Schwartz O, Alcover A: Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse.

    Immunity 2006, 24:547-561.

53. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C: Toll-like receptor 3 promotes cross-priming to virus-infected cells.

    Nature 2005, 433:887-892.

54. Sporri R, Reis e Sousa C: Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function.

    Nat Immunol 2005, 6:163-170.

55. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N: Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.

    J Infect Dis 2004, 190:1919-1926.

56. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells.

    Proc Natl Acad Sci USA 2003, 100:2783-2788.

57. Wilson JA, Richardson CD: Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV.

    Infect Disord Drug Targets 2006, 6:43-56.

58. Bowen DG, Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection.

    Nature 2005, 436:946-952.

59. Martin P, Inchauspé G: Hepatitis C vaccines.

    Drug Discovery Today: Therapeutic Strategies, in press.

60. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A: A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.

    Nat Med 2006, 12:190-197.

61. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

    Antimicrob Agents Chemother 2006, 50:4182-4185.

62. Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M, Wainberg MA: Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.

    Antimicrob Agents Chemother 2006, 50:2210-2213.

63. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

    AIDS 2006, 20:F9-13.

64. Routy JP: Valproic acid: a potential role in treating latent HIV infection.

    Lancet 2005, 366:523-524.

65. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

    Nat Med 2006, 12:1198-1202.

66. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB: Interleukin-10 determines viral clearance or persistence in vivo.

    Nat Med 2006, 12:1301-1309.

67. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

    Nature 2002, 418:646-650.

68. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

    Proc Natl Acad Sci USA 2005, 102:8321-8326.

69. Suspene R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP: Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.

    J Gen Virol 2005, 86:125-129.

70. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J: Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.

    Hepatology 2006, 43:1364-1374.

71. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA: Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users.

    Am J Epidemiol 1994, 139:1153-1163.

72. Kaplan EH, Khoshnood K, Heimer R: A decline in HIV-infected needles returned to New Haven's needle exchange program: client shift or needle exchange?

    Am J Public Health 1994, 84:1991-1994.

73. Ljungberg B, Christensson B, Tunving K, Andersson B, Landvall B, Lundberg M, Zall-Friberg AC: HIV prevention among injecting drug users: three years of experience from a syringe exchange program in Sweden.

    J Acquir Immune Defic Syndr 1991, 4:890-895.

74. Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Deren S, Torian L, Glebatis D, Murrill C, Monterroso E, Friedman SR: HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic.

    Am J Public Health 2000, 90:352-359.

75. Hurley SF, Jolley DJ, Kaldor JM: Effectiveness of needle-exchange programmes for prevention of HIV infection.

    Lancet 1997, 349:1797-1800.

76. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J, Vincelette J: High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study.

    Am J Epidemiol 1997, 146:994-1002.

77. Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, Schechter MT, O'Shaughnessy MV: Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

    AIDS 1997, 11:F59-65.

78. Rockwell R, Des Jarlais DC, Friedman SR, Perlis TE, Paone D: Geographic proximity, policy and utilization of syringe exchange programmes.

    AIDS Care 1999, 11:437-442.

79. Hutchinson SJ, Bird SM, Goldberg DJ: Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland.

    Hepatology 2005, 42:711-723.